W.-K. Hofmann - Concepedia

Author

W.-K. Hofmann

Also Known As

Hofmann W., W HOFMANN, W Hofmann, W-K Hofmann, W-K. Hofmann, W. Hofmann, W. K. Hofmann, W.-K. Hofmann, W.K. Hofmann, WK Hofmann

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Goethe University Frankfurt Universität Ulm Medizinische Hochschule Hannover Johannes Gutenberg University Mainz University Hospital Frankfurt

About

W.-K. Hofmann is an author at Goethe University Frankfurt specializing in medicine, hematology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	570
2	Health Sciences	3	3	162
3	Cell Biology	2	2	95
4	Education	1	1	137
5	Emergency Medicine	1	1	17

W.-K. Hofmann

Publications

859

Citations

H-Index

Page 1

	Year	Citations
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis Felicitas Thol, E. M. Weissinger, J. Krauter, Haematologica	2010	190
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes Michael Stadler, Ulrich Germing, Kliche Ko, Leukemia Equine-assisted TherapyAnimal HealthBone Marrow FailureAnimal ScienceHematology	2004	137
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study Ulrich Germing, Michael Lauseker, Barbara Hildebrandt, Leukemia Hematological MalignancyOncologyLeukemic TransformationUntreated PatientsCancer Treatment	2012	124
Infection of cultured intestinal epithelial cells with severe acute respiratory syndrome coronavirus Jindřich Činátl, Gerold Hoever, Birgit Morgenstern, Cellular and Molecular Life Sciences	2004	87
Discovery of epigenetically silenced genes in acute myeloid leukemias Julian C. Desmond, Sophie Raynaud, Emily W. Y. Tung, Leukemia ChromatinMixed-phenotype Acute LeukemiaGeneticsAcute Myeloid LeukemiasEpigenomics	2007	64
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia W.-K. Hofmann, Gerhard Heil, C. Zander, Annals of Hematology Hematological MalignancyOncologyG-csf PrimingMedicineHematology	2004	56
Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia Mohamad Jawhar, Nicole Naumann, Marcin Knut, Leukemia Hematological MalignancyMyeloid NeoplasmsGeneticsHematologyPathology	2017	49
BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia Sandra Heesch, Cornelia Schlee, Martín Neumann, Leukemia Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaMalignant Blood DisorderImmunology	2010	46
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML) Arnold Ganser, Gerhard Heil, G. Seipelt, Annals of Hematology Hematological MalignancyOncologyMixed-phenotype Acute LeukemiaMalignant Blood DisorderImmunology	2000	25
Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia W.-K. Hofmann, G. Seipelt, S. Langenhan, Annals of Hematology Hematological MalignancyOncologyFactor Administration SchedulesHigh-dose Cytarabine TherapyMalignant Blood Disorder	2002	21

Page 1